<DOC>
	<DOCNO>NCT00451386</DOCNO>
	<brief_summary>This study investigate safety efficacy ertapenem versus ceftriaxone pediatric patient urinary tract infection , skin infection , community-acquired pneumonia .</brief_summary>
	<brief_title>Ertapenem Study Pediatric Patients Who Have Urinary Tract Infections , Skin Infections Community-acquired Pneumonia ( 0826-036 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>Patients UTI must white blood cell bacteria urine bladder catheterization urologic abnormality , kidney infection Patients SSTI must recent infection Patients CAP must chest xray indicate bacterial pneumonia fever Patients complete urinary tract blockage kidney abscess Patients infected burn wound , bone infection , bacterial arthritis Patients mechanical ventilation cystic fibrosis , chronic lung disease pus space chest wall lung</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>